OverviewChartNewsTraderScreen

Vaccinex/  US9186403013  /

IEX
2024-11-15  6:57:26 PM Chg. -0.19 Volume Bid- Ask- High Low
3.34USD -5.38% 300
Turnover: 1,079.37		 -Bid Size: - -Ask Size: - 3.73 3.34
GlobeNewswire 08-14 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 07-31 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire 07-17 Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire 06-06 Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire 05-16 Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 04-02 Vaccinex Reports 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03-27 Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Pr...
GlobeNewswire 02-21 Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
GlobeNewswire 02-15 Vaccinex, Inc. Announces Reverse Stock Split
GlobeNewswire 02-07 Vaccinex Announces Pricing of $3.7 Million PIPE Financing
GlobeNewswire 01-03 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire 2023-12-04 Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire 2023-11-13 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-10-31 Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combinat...
GlobeNewswire 2023-10-26 Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Ne...
GlobeNewswire 2023-09-29 Vaccinex Announces Pricing of $9.6 Million Public Offering
GlobeNewswire 2023-09-28 Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Va...
GlobeNewswire 2023-09-27 Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
GlobeNewswire 2023-09-26 Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab ...
GlobeNewswire 2023-09-22 Vaccinex, Inc. Announces Reverse Stock Split
GlobeNewswire 2022-02-24 Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
GlobeNewswire 2022-01-27 Vaccinex Announces $6.6 Million Private Placement
GlobeNewswire 2022-01-26 Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B...
GlobeNewswire 2021-11-10 Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
GlobeNewswire 2021-11-09 Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting